Publications

PDX Data Commons and Coordinating Center

Publications

2023

A pan-cancer PDX histology image repository with genomic and pathological annotations for deep learning analysis, White, BS, Woo, X, Koc, S, Sheridan, T, Neuhauser, SB, Wang, S, Evrard, YA, Landua, JD, Mashl, RJ, Davies, SR, Fang, B, Raso, MG, Evans, KW, Bailey, MH, Chen, Y, Xiao, M, Rubinstein, J, Pour, AF, Dobrolecki, LE,  Fujita, M, Fujimoto, J, Xiao, G, Fields, RC, Mudd, JL, Xu, X, Hollingshead, MG, Jiwani, S, PDXNet Consortium, Davis-Dusenbery, B, Wallace, TA, Moscow, JA, Doroshow, JH, Mitsiades, N, Kaochar, SK, Pan, CX, Chen Jr, MS, Carvajal-Carmona, LG, Welm, AL, Welm, BE, Govindan, R, Li, S, Davies, MA, Roth, JA, Meric-Bernstam, F, Xie, Y, Herlyn, M, Ding, L, Lewis, MT Bult, CJ, Dean II, DA, Chuang, JH, 2022, In Press

Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: a National Cancer Institute Patient-Derived Xenograft Development and Trial Center Research Network (PDXNet) Report, Meric-Bernstam, F, Lloyd, MW, Koc, S, Evrard, Y, Dean II, DA, McShane, LM, Lewis, MT, Evans, K, Li, D, Rubinstein, L, Welm, AL, Srivastava, A, Grover, JW, Ha, M, MJ-H, Chen, H, Huang, X, Wang, J, Roth, J, Welm, BE, Govinden, R, Ding, L, Kaochar, S, Mitsiades, N, Carvajal-Carmona, PDXNET Consortium, Herylyn, M, Davies, MA, Doroshow, JH, Chuang, JH, Moscow, JA, 2022, In Press

Development, and application of genetic ancestry reconstruction methods to study the diversity of patient-derived models in the NCI PDXNet Consortium, Sanderson, BJ, Lott, P, Chiu, K, Quino, JE, Vang, AP, Lloyd, ML, Srivastava, A, PDXNet Consortium, Chuang, JH, Carvajal-Carmona, LG, 2022, Under Review

2022

PDXNet Portal: Patient-Derived Xenograft model, data, workflow, and tool discovery. Koc, S, Lloyd, MW, Grove, J, Seepo, S, Subramanian, SL, Ray, M, Frech, C, DiGiovanna, J, Webster, P, Neuhauser, S, Srivastava, A, Woo, XY, Sanderson, BJ, White, B, Lott, P, PDXNet Consortium, Evard, YA, Wallace, TA, Moscow, JA, Doroshow, JH, Mitsuades, N, Kochar, S, Pan, C, Chen, MS, Carvajal-Carmona, L, Welm, AL, Welm, BE, Lewis, MT, Ramaswamy, G, Ding, L, Li, S, Herlyn, M, Davies, M, Roth, J, Meric-Bernstam, F, Robinson, PN, Bult, CJ, Davis-Dusenbery, B, Dean II, DA, Chuang, JH, Nucleic Acid Research Cancer

2021

Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Sun, H., Cao, S., Mashl, R.J. et al.  Nat Commun 12, 5086 (2021). https://doi.org/10.1038/s41467-021-25177-3

2020

PDXNET consortium, EurOPDX consortium, Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts, Woo, XY, Giordano, J, Srivastava, A, Zhao, ZM, Lloyd, MW, de Bruijn, R, Suh, Y-S, Patidar, R, Chen, L, Scherer, S, Bailey, M, Yang, C-H, Cortes-Sanchez, E, Xi, Y, Jing Wang, J, Wickramasinghe, J, Kossenkov, AV, Rebecca, V, Sun, H, Mashl, RJ, Davies, S, Jeon, R, Frech, C, Randjelovic, J, Rosains, J, Galimi, F, Bertotti, A, Lafferty, A, O’Farrell, AC, Modave, E, Lambrechts, D, Brugge, P, Serra, V, Marangoni, E, Botty, RE, Kim, H, Kim, J-I, Yang, H-K, Lee, C, Dean II, DA, Davis-Dusenbery, B, Evrard, YA, Doroshow, JH, Welm, AL, Welm, BE, Lewis, MT, Fang, B, Roth, JA, Meric-Bernstam, F, Herlyn, M, Davies, M, Ding, L, Li, S, Govindan, R, Isella, C, Moscow, JA, Trusolino, L, Byrne, AT, Jonkers, J, Bult, CJ, Medico, E, Chuang, JH, 2020, Nature Genetics, doi: 10.1038/s41588-020-00750-6

2019

Systematic Establishment of Robustness and Standards in Patient-Derived Xenograft Experiments and Analysis, Evrard, YA, Srivastava, AJ, Randjelovic, J, PDXNet Consortium, Dean II, DA, Morris, JS, Chuang, JH, Cancer Research, 2020, doi: 10.1158/0008-5472.CAN-19-3101

PDX Development and Trial Center

Publications

The following are publications generated in the first PDXNet funding cycle.

  1. Alicea GM, Rebecca VW. Emerging strategies to treat rare and intractable subtypes of melanoma. Pigment Cell Melanoma Res. 2021;34:44-58. PMID: 32274887; PMCID: PMC7544642

  2. Aloia A, Müllhaupt D, Chabbert CD, Eberhart T, Flückiger-Mangual S, Vukolic A, Eichhoff O, Irmisch A, Alexander LT, Scibona E, Frederick DT, Miao B, Tian T, Cheng C, Kwong LN, Wei Z, Sullivan RJ, Boland GM, Herlyn M, Flaherty KT, Zamboni N, Dummer R, Zhang G, Levesque MP, Krek W, Kovacs WJ. A fatty acid oxidation-dependent metabolic shift regulates the adaptation of BRAF-mutated melanoma to MAPK inhibitors. Clin Cancer Res. 2019;25:6852-6867. PMID: 31375515; PMCID: PMC6906212

  3. Amaral R, Zimmermann M, Ma AH, Zhang H, Swiech K, Pan CX.  A Simple Three-Dimensional In Vitro Culture Mimicking the In Vivo-Like Cell Behavior of Bladder Patient-Derived Xenograft Models. Cancers (Basel). 2020;12:1304.

  4. Atay C, Kwak T, Lavilla-Alonso S, Donthireddy L, Richards A, Moberg V, Pilon-Thomas S, Schell M, Messina JL, Rebecca VW, Xiao M, Tan J, Zhang G, Weber JS, Herlyn M, Sarnaik AA, Gabrilovich DI. BRAF targeting sensitizes resistant melanoma to cytotoxic T cells. Clin Cancer Res. 2019;25:2783-2794. PMID: 30765391; PMCID: PMC6497575.

  5. Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ, Boland G, Flaherty K, Herlyn M, Ruppin E. Robust prediction of response to immune checkpoint blockade theapy in metastatic melanoma. Nat Med. 2018;24:1545-1549. PMID: 30127394; PMCID: PMC6693632.

  6. Baity M, Wang L, Correa AM, Zhang X, Zhang R, Pataer A, Wu S, Meng QH, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Zhao M, Gu J,  Fang B. Glutathione reductase (GSR) gene deletion and chromosome 8 aneuploidy in primary lung cancers detected by fluorescence in situ hybridization. Am J Cancer Res. 9:1201-1211;2019. PMID 31285952.  PMCID: PMC6610060

  7. Buj R, Chen CW, Dahl ES, Leon KE, Kuskovsky R, Maglakelidze N, Navaratnarajah M, Zhang G, Doan MT, Jiang H, Zaleski M, Kutzler L, Lacko H, Lu Y, Mills GB, Gowda R, Robertson GP, Warrick JI, Herlyn M, Imamura Y, Kimball SR, DeGraff DJ, Snyder NW, Aird KM. Suppression of p16 induces mTORC1-mediated nucleotide metabolic reprogramming. Cell Rep. 2019;28:1971-1980. PMID: 31433975; PMCID: PMC6716532

  8. Bulle A, Lim KH: Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer. Signal Transduct Target Ther 2020, 5:249. PMID: 33122631; PMCID: PMC7596088.

  9. Bulle A, Lim KH: Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer. Signal Transduct Target Ther 2020, 5:249. PMID: 33122631; PMCID: PMC7596088.

  10. Chen Y, Zhang R, Wang L, Correa AM, Pataer A, Xu Y, Zhang X, Ren C, Wu S, Meng QH, Fujimoto J, Jensen VB, Antonoff MB, Hofstetter WL, Mehran RJ, Pisimisis G, Rice DC, Sepesi B, Vaporciyan AA, Walsh GL, Swisher SG, Roth JA, Heymach JV, Fang B. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice. Cancer, 125:3738-37-48;2019. PMID: 31287557. PMCID: PMC7294643

  11. 11.   Chen, F, Wendl, MC, Wyczalkowski, M, Bailey, MH, Li, Y, Ding, L, Pan-Cancer Studies: Evolving from Basic Research Toward the Clinic, Under Review at Nature Cancer, 2021

  12. Das I, Chen H, Maddalo G, Tuominen R, Rebecca VW, Herlyn M, Hansson J, Davies MA, Egyházi Brage S. Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma. Cell Death Dis. 2020;11:882. PMID: 33082316; PMCID: PMC7576205

  13. Davies MA, Flaherty KT. Melanoma in 2017: Moving treatments earlier to move further forwards. Nat Rev Clin Oncol. 2018;15:75-76. PMID: 29182162; PMCID: PMC7436336.

  14. Davies MA. Is it safe to stop Anti-PD-1 immunotherapy in patients with metastatic melanoma who achieve a complete response? J Clin Oncol. 2020;38:1645-1647. PMID: 32097093; PMCID: PMC7238487

  15. Devarakonda S, Govindan R: Targeting Resistance to Targeted Therapies: Combating a Resilient Foe. Clin Cancer Res 2018, 24:6112-6114. PMID: 30352903; PMCID: PMC6295273.

  16. Devarakonda S, Govindan R: Targeting Resistance to Targeted Therapies: Combating a Resilient Foe. Clin Cancer Res 2018, 24:6112-6114. PMID: 30352903; PMCID: PMC6295273.

  17. Evrard YA, Srivastava A, Randjelovic J, Doroshow JH, Dean DA 2nd, Morris JS, Chuang JH; NCI PDXNet Consortium. Systematic establishment of robustness and standards in patient-derived xenograft experiments and analysis. Cancer Res. 2020;80:2286-2297.PMID: 32152150; PMCID: PMC7272270

  18. Evrard YA, Srivastava A, Randjelovic J, Doroshow JH, Dean DA, 2nd, Morris JS, Chuang JH, Consortium NCIP: Systematic Establishment of Robustness and Standards in Patient-Derived Xenograft Experiments and Analysis. Cancer Res 2020, 80:2286-2297. PMID: 32152150; PMCID: PMC7272270.

  19. Gómez-Miragaya J, Díaz-Navarro A, Tonda R, Beltran S, Palomero L, Palafox M, Dobrolecki LE, Huang C, Vasaikar S, Zhang B, Wulf GM, Collado-Sole A, Trinidad EM, Muñoz P, Paré L, Prat A, Bruna A, Caldas C, Arribas J, Soler-Monso MT, Petit A, Balmaña J, Cruz C, Serra V, Pujana MA, Lewis MT, Puente XS, González-Suárez E. Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. Cancer Res. 2019 Aug 15;79(16):4258-4270. doi: 10.1158/0008-5472.CAN-18-3835. Epub 2019 Jun 18. PMID: 31213465.

  20. Gómez-Miragaya J, Morán S, Calleja-Cervantes ME, Collado-Sole A, Paré L, Gómez A, Serra V, Dobrolecki LE, Lewis MT, Diaz-Lagares A, Eroles P, Prat A, Esteller M, González-Suárez E. The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models. Mol Cancer Res. 2019 Oct;17(10):2063-2076. doi: 10.1158/1541-7786.MCR-19-0040. Epub 2019 Jul 18. PMID: 31320385.

  21. Griss J, Bauer W, Wagner C, Simon M, Chen M, Grabmeier-Pfistershammer K, Maurer-Granofszky M, Roka F, Penz T, Bock C, Zhang G, Herlyn M, Glatz K, Läubli H, Mertz KD, Petzelbauer P, Wiesner T, Hartl M, Pickl WF, Somasundaram R, Steinberger P, Wagner SN. B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat Commun. 2019;10:4186. PMID: 31519915; PMCID: PMC674445

  22. Gu G, Tian L, Herzog SK, Rechoum Y, Gelsomino L, Gao M, Du L, Kim JA, Dustin D, Lo HC, Beyer AR, Edwards DG, Gonzalez T, Tsimelzon A, Huang HJ, Fernandez NM, Grimm SL, Hilsenbeck SG, Liu D, Xu J, Alaniz A, Li S, Mills GB, Janku F, Kittler R, Zhang XH, Coarfa C, Foulds CE, Symmans WF, Ando S, Fuqua SAW, Oncogene 2021 Feb;40(5):997-101, Hormonal Modulation of ESR1 Mutant Metastasis

  23. Guillen, KP, Fujita, M, Butterfield, AJ, Scherer, SD, Bailey, MH,  Chu, Z, DeRose, YS, Zhao, L,  Cortes-Sanchez, E, Yang, C-H, Toner, J, Wang, G,Qiao, Y, Huang, X, Greenland,  JA, Vahrenkamp, JM, Lum, DH, Factor, RE, Nelson, EW, Matsen, CB, Poretta, JM, Rosenthal, R,Beck, AC, Buys, SS, Vaklavas, C, John H Ward, JH, Randy L Jensen, RL, Kevin B Jones, KB, Li, Z, Oesterreich, S, Dobrolecki, LE, Pathi, SS, Woo, XY, Berrett, KC, Wadsworth, ME, Chuang, JH, Lewis, MT, Marth, GT, Gertz, JG, Varley, KE, Welm, BE, Welm, AL, A breast cancer patient-derived xenograft and organoid platform for drug discovery and precision oncology, bioRxiv, 2021.02.28.433268; doi: https://doi.org/10.1101/2021.02.28.433268

  24. Guo Z, Primeau T, Luo J, Zhang C, Sun H, Hoog J, Gao F, Huang S et al: Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models. Cancers (Basel) 2020, 12 PMID: 33371187; PMCID: PMC7765949.

  25. Jiang H, Liu X, Knolhoff BL, Hegde S, Lee KB, Jiang H, Fields RC, Pachter JA et al: Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion. Gut 2020, 69:122-132. PMID: 31076405; PMCID: PMC7167297.

  26. Kaochar S, Mitsiades N. Glucocorticoids mediate adverse events of deep androgen receptor axis inhibition in prostate cancer patients. Ann Oncol. 2020 Mar;31(3):323-325. PMID: 32067673.

  27. Katleba K, Lombard AP, Tsamouri MM, Baek HB, Nishida KS, Libertini SJ, Platero AJ, Ma AH, Pan CX, Ghosh PM, Mudryj M. Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis. Cancer Lett. 2021 Feb 4:S0304-3835(21)00061-6. doi: 10.1016/j.canlet.2021.01.029. Epub ahead of print. PMID: 33549708.

  28. Kawakami M, Mustachio LM, Chen Y, Chen Z, Liu X, Wei CH, Roszik J, Kittai AS, Danilov AV, Zhang X, Fang B, Wang J, Heymach JV, Tyutyunyk-Massey L, Freemantle SJ, Kurie JM, Liu X and Dmitrovsky E. A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis and Metastasis in Aneuploid Cancers. Mol Cancer Ther 2020; PMID: 33277443

  29. Kim MJ, Cervantes C, Jung YS, Zhang X, Zhang, J, Lee SH, Jun S, Litovchick L, Wang W, Chen J, Fang B, Park JI. PAF Remodels the DREAM Complex to Bypass Cell Quiescence and Promote Lung Tumorigenesis. Molecular Cell 2021 Jan, in press. 

  30. Lazar I, Fabre B, Feng Y, Khateb A, Turko P, Martinez Gomez JM, Frederick DT, Levesque MP, Feld L, Zhang G, Zhang T, James B, Shklover J, Avitan-Hersh E, Livneh I, Scortegagna M, Brown K, Larsson O, Topisirovic I, Wolfenson H, Herlyn M, Flaherty K, Dummer R, Ronai ZA. SPANX control of Lamin A/C modulates nuclear architecture and promotes melanoma growth. Mol Cancer Res. 2020;18:1560-1573. PMID: 3257198; PMCID: PMC7541784

  31. Liu X, Olszewski K, Zhang Y, Lim EW, Shi J, Zhang X, Zhang J, Lee H, Koppula P, Lei G, Zhuang L, You MJ, Fang B, Li W, Metallo CM, Poyurovsky MV and Gan B. Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer. Nat Cell Biol 2020; 22: 476-486. PMID: 32231310. PMCID: PMC7194135

  32. Long Q, Ma AH, Zhang H, Cao Z, Xia R, Lin TY, Sonpavde GP, de Vere White R, Guo J, Pan CX. Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer. Cancer Immunol Immunother. 2020; 69:2305-2317.

  33. Martin KA, Hum NR, Sebastian A, He W, Siddiqui S, Ghosh PM, Pan C, de Vere White R, Loots GG. Methionine Adenosyltransferase 1a (MAT1A) Enhances Cell Survival During Chemotherapy Treatment and is Associated with Drug Resistance in Bladder Cancer PDX Mice. Intl J Mol Science. 2019 20: pii: E4983

  34. Meraz IM, Majidi M, Meng F, Shao R, Ha MJ, Neri S, Fang B, Lin SH, Tinkey PT, Shpall EJ, Morris J, Roth JA. Development of an improved humanized patient-derived xenograft mouse model for evaluation of antitumor immune response in lung cancer. Cancer Immunol Res. 7:1267-1279;2019 PMCID: PMC7213862

  35. Miranda MA, Marcato PD, Mondal A, Chowdhury N, Gebeyehu A, Surapaneni SK, Bentley MVLB, Amaral R, Pan CX, Singh M. Cytotoxic and chemosensitizing effects of glycoalkaloidic extract on 2D and 3D models using RT4 and patient derived xenografts bladder cancer cells. Mater Sci Eng C Mater Biol Appl. 2021; 119:111460.

  36. Mondal AM, Ma A, Li G, Krawczyk E, Lu J, Schlegel R, Pan C†*, Liu X†*. Fidelity of a PDX-CR model for bladder cancer. Biochem Biophys Res Commun. 2019. 517:49.

  37. Neurofibromin Is an Estrogen Receptor-alpha Transcriptional Co-repressor in Breast Cancer. Zheng, Z. et al Cancer Cell. 2020 Mar 16;37(3):387-402.e7. doi: 10.1016/j.ccell.2020.02.003. Epub 2020 Mar 5.

  38. Owusu-Brackett, N., Evans, K. W., Akcakanat, A., Yuca, E., Tapia, C., Rizvi, Y. Q., Dumbrava, E. I., Janku, F., & Meric-Bernstam, F. (2019). TAK228 enhances antitumor activity of eribulin in triple negative breast cancer. Oncotarget, 10(49), 5011–5019. PMID: 31489111. PMCID: PMC6707945.

  39. Pu, X.; Zhang, R.; Wang, L.; Chen, Y.; Xu, Y.; Pataer, A.; Meraz, I. M.; Zhang, X.; Wu, S.; Wu, L.; Su, D.; Mao, W.; Heymach, J. V.; Roth, J. A.; Swisher, S. G.; Fang, B. Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer. J Transl Med 2018, 16, 328. PMID: 30477533. PMCID: PMC6260563

  40. Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, Li S, Chen T, Han H, Negrao MV, Ahnert JR, Diao L, Wang J, Le X, Meric-Bernstam F, Routbort M, Roeck B, Yang Z, Raymond VM, Lanman RB, Frampton GM, Miller VA, Schrock AB, Albacker LA, Wong KK, Cross JB, Heymach JV. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell. 2019 Oct 14;36(4):444-457.e7. doi: 10.1016/j.ccell.2019.09.001. Epub 2019 Oct 3. PMID: 31588020. PMCID: PMC: PMC6944069.

  41. Sanghoon Lee, Yiheng Hu, Suet Kee Loo, Ying Tan, Rohit Bhargava, Michael T. Lewis, Xiao-Song Wang. Landscape analysis of adjacent gene rearrangements reveals BCL2L14–ETV6 gene fusions in more aggressive triple-negative breast cancer. Proceedings of the National Academy of Sciences May 2020, 117 (18) 9912-9921; DOI: 10.1073/pnas.1921333117 PMID: 32321829

  42. Satpathy S, Jaehnig EJ, Krug K, Kim BJ, Saltzman AB, Chan DW, Holloway KR, Anurag M, Huang C, Singh P, Gao A, Namai N, Dou Y, Wen B, Vasaikar SV, Mutch D, Watson MA, Ma C, Ademuyiwa FO, Rimawi MF, Schiff R, Hoog J, Jacobs S, Malovannaya A, Hyslop T, Clauser KR, Mani DR, Perou CM, Miles G, Zhang B, Gillette MA, Carr SA, Ellis MJ. Microscaled proteogenomic methods for precision oncology. Nat Commun. 2020 Jan 27;11(1):532. doi: 10.1038/s41467-020-14381-2. PMID: 31988290; PMCID: PMC6985126.

  43. Savaikar MA, Whitehead T, Roy S, Strong L, Fettig N, Prmeau T, Luo J, Li S et al: Preclinical PERCIST and 25% of SUVmax Threshold: Precision Imaging of Response to Therapy in Co-clinical (18)F-FDG PET Imaging of Triple-Negative Breast Cancer Patient-Derived Tumor Xenografts. J Nucl Med 2020, 61:842-849. PMID: 31757841; PMCID: PMC7262224.

  44. Savaikar MA, Whitehead T, Roy S, Strong L, Fettig N, Prmeau T, Luo J, Li S et al: Preclinical PERCIST and 25% of SUVmax Threshold: Precision Imaging of Response to Therapy in Co-clinical (18)F-FDG PET Imaging of Triple-Negative Breast Cancer Patient-Derived Tumor Xenografts. J Nucl Med 2020, 61:842-849. PMID: 31757841; PMCID: PMC7262224.

  45. Singh, R.; Peng, S.; Viswanath, P.; Sambandam, V.; Shen, L.; Rao, X.; Fang, B.; Wang, J.; Johnson, F. M. Non-canonical cMet regulation by vimentin mediates Plk1 inhibitor-induced apoptosis. EMBO Mol Med 2019, 11, e9960. PMID: 31040125. PMCID: PMC6505578

  46. Somasundaram R, Connelly T, Choi R, Choi H, Samarkina A, Li L, Gregorio E, Chen Y, Thakur R, Abdel-Mohsen M, Beqiri M, Kiernan M, Perego M, Wang F, Xiao M, Brafford P, Yang X, Xu X, Secreto A, Danet-Desnoyers G, Traum D, Kaestner KH, Huang AC, Hristova D, Wang J, Fukunaga-Kalabis M, Krepler C, Ping-Chen F, Zhou X, Gutierrez A, Rebecca VW, Vonteddu P, Dotiwala F, Bala S, Majumdar S, Dweep H, Wickramasinghe J, Kossenkov AV, Reyes-Arbujas J, Santiago K, Nguyen T, Griss J, Keeney F, Hayden J, Gavin BJ, Weiner D, Montaner LJ, Liu Q, Peiffer L, Becker J, Burton EM, Davies MA, Tetzlaff MT, Muthumani K, Wargo JA, Gabrilovich D, Herlyn M. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nat Commun. 2021;12:346. PMID: 33436641; PMCID: PMC7804257

  47. Sun, H, Cao, S, Jay Mashl, RJ, Mo, C-K, Zaccaria, S, Wendl, MC, Davies, SR, Bailey, MH, Primeau, TM, Hoog, J, Mudd, JL, Dean II, DA, Patidar, R, Chen, L, Wyczalkowski, MA, Jayasinghe, RG, Rodrigues, FM, Terekhanova, NV, Li, Y, Lim, K-H, Wang-Gillam, A, Van Tine, BA, Ma, CX, Aft, R, Fuh, KC, Dipersio, JF, The NCI PDXNet Consortium, Davis-Dusenbery, B, Lewis, MT, Davies, M, Herlyn, M, Fang, B, Roth, JA, Welm, AL, Welm, BE, Meric-Bernstam, F, Chen, F, Fields, RC, Li, S, Govindan, R, Doroshow, JH, Moscow, JA, Yvonne A. Evrard, YA, Chuang, JH, Raphael, BJ, Li Ding, L, Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment, Submitted to Nature Communications, 2021

  48. Wang X, Veeraraghavan J, Liu CC, Cao X, Qin L, Kim JA, Tan Y, Loo SK, Hu Y, Lin L, Lee S, Shea M, Mitchell T, Li S, Ellis MJ, Hilsenbeck SG, Schiff R, Wang XSClin Cancer Res 2021 Feb 4; Therapeutic Targeting of Nemo-Like Kinase in Primary and Acquired Endocrine-Resistant Breast Cancer[Epub ahead of print]

  49. Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA, 2nd, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E and Chuang JH. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet 2021; 53: 86-99. PMID: 33414553. PMCID: PMC7808565.

  50. Wu F, Hua Y, Kaochar S, Nie S, Lin YL, Yao Y, Wu J, Wu X, Fu X, Schiff R, Davis CM, Robertson M, Ehli EA, Coarfa C, Mitsiades N, Song Y. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP. J Med Chem. 2020 May 14;63(9):4716-4731. Epub 2020 Apr 21. PMID: 32314924; PMCID: PMC7340344.

  51. Xiao M, Rebecca VW, Herlyn M. A melanoma-derived xenograft model. J Vis Exp. 2019;(147). PMID: 31157772; PMCID: PMC6986799.

  52. Yan, X.; Zhang, X.; Wang, L.; Zhang, R.; Pu, X.; Wu, S.; Li, L.; Tong, P.; Wang, J.; Meng, Q.; Jensen, V. B.; Girard, L.; Minna, J. D.; Roth, J. A.; Swisher, S. G.; Heymach, J. V.; Fang, B. Inhibition of thioredoxin/thioredoxin reductase induces synthetic lethality in lung cancers with compromised glutathione homeostasis. Cancer Res 2019, 79, 125-132. PMID: 30401714. PMCID: PMC7293542

  53. Yuan G, Flores NM, Hausmann S, Lofgren SM, Kharchenko V, Angulo-Ibanez M, Czaban I, Azhibek D, Fischle W, Jaremko M, Wistuba II, Chua K, Roth JA, Minna JD, Shao NY, Jaremko L, Mazur PK, Gozani O. Elevated NSD3 Histone Methylation Activity Drives Squamous Cell Lung Cancer. Nature, 2021 Feb;590(7846):504-508. PMID: 33536620. 

  54. Zhang X, Zhang R, Chen H, Wang L, Ren C, Pataer A, Wu S, Meng QH, Ha MJ, Morris J, Xi Y, Wang J, Zhang J, Gibbons DL, Heymach JV, Meric-Bernstam F, Minna J, Swisher SG, Roth JA and Fang B. KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. Am J Cancer Res 2020; 10: 4464-4475. PMID: 33415011. PMCID: PMC7783771

  55. Zhao, M., Scott, S., Evans, K.W., Yuca, E., Saridogan, T., Zheng, X., Wang, H., Korkut, A., Cruz Pico, C.X., Demirhan, M., Kirby, B., Kopetz, S., Diala, I., Lalani, A.S., Piha-Paul, S., Meric-Bernstam, F. Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer. Clin Cancer Res. 2021 Jan 07. PMID: 33414137.

Funding provided by the NIH to the PDXNet Data Commons and Coordination Center (NCI U24-CA224067), to the PDX Development and Trial Centers (NCI U54-CA224083, NCI U54-CA224070, NCI U54-CA224065, NCI U54-CA224076, NCI U54-CA233223, and NCI U54-CA233306) and to the National Cancer Institute Cancer Genomics Cloud (HHSN261201400008C and HHSN261201500003I).